DR Ilias Goranitis

DR Ilias Goranitis


  • Decision-analytic modelling
  • Discrete choice modelling
  • Genomics
  • Health economic evaluation
  • Outcome measurement and valuation



  • Ilias Goranitis is a senior health economics research fellow specialising in the economic evaluation and outcome valuation of genomic technologies. His main applied and methodological work focuses on exploring the cost-effectiveness of genomic technologies as well as the individual preferences for genomic testing using health economic and discrete choice modelling. Dr Goranitis is jointly working between the Centre for Health Policy at the University of Melbourne and the Australian and Melbourne Genomic Health Alliances at the Murdoch Children’s Research Institute (MCRI), aiming to provide health economic evidence for the implementation of genomic medicine that will inform state and federal government policy. Prior to joining the University of Melbourne, Dr Goranitis was a research fellow and deputy director of teaching on health economics at the University of Birmingham. Dr Goranitis has been a successful co-applicant in research grants from the NIHR HTA and the Department of Health in the UK (Calibre trial, Mifemiso trial, PPH study, Shifting shapes study) worth £5 million (AU$ 9 million), and he has been a health economics investigator in large NIHR-funded health technology assessments (Trapeze trial, Prism trial and BUS study) and research for patient benefit (SBNT study) programmes as well as a large multinational trial funded by the MRC, the Wellcome Trust, and the Department for International Development in the UK (AIMS trial). His work has been published in high impact journals, such as Health Technology Assessment, JAMA oncology, Medical Decision Making, PharmacoEconomics, Value in Health, Plos ONE, Quality of Life Research, and he has contributed to a book on Mental Health Economics published by Springer International. Dr Goranitis has collaborated on research with the National Institute for Health and Care Excellence (NICE) in the UK and has offered health economics advice as part of the NIHR Research Design Service (West Midlands). He has signific   


Member of

  • International Health Economics Association (iHEA). Member 2015 -
  • Health Economists' Study Group (HESG). Member 2012 -


Selected publications


Additional Grant Information

  • Research Grants (Approved) – Co-applicant (1) Title: Uterotonic drugs for preventing postpartum haemorrhage: A network meta-analysis and cost-effectiveness analysis (14/139/17). Funding body: NIHR HTA Lead applicant: Prof Arri Coomarasamy Co-applicants for health economics: TE Roberts & I Goranitis Period: May 2015-August 2016 (15 months) Research cost: £197,470 (2) Title: Shifting Shapes: How can local care markets support quality and choice for all? Funding body: UK Department of Health PRP Lead applicant: Dr Catherine Needham Co-applicant and lead for health economics: I Goranitis Period: October 2016 (30 months) Research cost: £555,303 (3) Title: A randomised trial of mifepristone and misoprostol versus misoprostol alone in the medical management of missed miscarriage: The MIFEMISO trial Funding body: NIHR HTA Lead applicant: Prof Arri Coomarasamy Co-applicants for health economics: TE Roberts & I Goranitis Duration: 3 years Research cost: £1,700,000 (4) Title: Primary prevention of variceal bleeding in patients with liver cirrhosis Funding body: NIHR HTA Lead applicant: Dr Dhiraj Tripathi Co-applicant and lead for health economics: I Goranitis Period: January 2018 (75 months) Research cost: £2,342,151.18 Research Grants (Approved) – health economics investigator (a) Title: Effectiveness of antibiotic prophylaxis during surgical evacuation of the uterus for miscarriage management in low income countries: a multinational, randomised, double-blind placebo-controlled trial. Funding body: MRC, Wellcome, Department for International Development (UK) Lead applicant: Prof Arri Coomarasamy Duration: August 2014 (36 months) Research cost: £1,649,550 (b) Title: Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: A randomised placebo-controlled trial (The PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial). Funding body: NIHR HTA Lead applicant: Prof Arri Coomarasamy Duration: June 2015 (36 months) Research    


Education and training

  • PhD, University of Athens 2013
  • MSc, London School of Economics and Political Science 2012


Available for supervision

  • Y